Hematology

TCRαβ-DEPLETED PROGENITOR CELL GRAFT WITH ADDITIONAL MEMORY T-CELL DLI, PLUS SELECTED USE OF BLINATUMOMAB, IN NAÏVE T-CELL DEPLETED HAPLOIDENTICAL DONOR HEMATOPOIEITC CELL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES

Conditions:   Acute Lymphoblastic Leukemia (ALL);   Acute Myeloid Leukemia (AML);   Myelodysplastic Syndromes (MDS);   NK-Cell Leukemia;   Hodgkin Lymphoma;   Non Hodgkin Lymphoma (NHL);   Juvenile Myelomonocytic Leukemia (JMML);   Chronic Myeloid Leukemia (CML)
Interventions:   Drug: Cyclophosphamide;   Biological: Fludarabine;   Drug: Thiotepa;   Drug: Melphalan;   Biological: G-csf;   Drug: Mesna;   Device: CliniMACS;   Biological: ATG (rabbit);   Drug: Blinatumomab;   Biological: TCRα/β+;   Biological: CD19+;   Biological: CD45RA-depleted DLI
Sponsor:   St. Jude Children’s Research Hospital
Recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

February 21, 2019 / by / in
SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies

Conditions:   Advanced Malignant Solid Neoplasm;   Extracranial Solid Neoplasm;   Metastatic Malignant Solid Neoplasm
Interventions:   Biological: Anti-OX40 Antibody BMS 986178;   Drug: TLR9 Agonist SD-101
Sponsors:   Stanford University;   Bristol-Myers Squibb
Not yet recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

February 17, 2019 / by / in
A Phase 1 Study to Evaluate Safety, Tolerability, and PK of TBI-223 in Healthy Adults

Conditions:   Tuberculosis;   Tuberculosis, Pulmonary
Interventions:   Drug: TBI-223 50mg;   Drug: Placebo for TBI-223 50mg;   Drug: TBI-223 100, 300, 600, 1200, 1400 mg;   Drug: Placebo for TBI-223 100, 300, 600, 1200, 1400 mg
Sponsor:   Global Alliance for TB Drug Development
Recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

February 15, 2019 / by / in